BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 11, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-vWF Nanobody: Phase II started

Ablynx began a single-blind, placebo-controlled, international Phase II trial in 110 patients to evaluate a single 10 mg IV bolus of anti-vWF Nanobody prior to plasma exchange, followed...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >